Tissue Regenix Group plc
TRX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | – | £0 | £0 |
| % Growth | – | – | 186.9% | – |
| Cost of Goods Sold | £0 | – | £0 | £0 |
| Gross Profit | £0 | – | £0 | £0 |
| % Margin | 41.8% | – | 52.5% | 55.3% |
| R&D Expenses | £0 | – | £0 | £0 |
| G&A Expenses | £0 | – | £0 | £0 |
| SG&A Expenses | £0 | – | £0 | £0 |
| Sales & Mktg Exp. | £0 | – | -£0 | £0 |
| Other Operating Expenses | £0 | – | £0 | £0 |
| Operating Expenses | £0 | – | £0 | £0 |
| Operating Income | -£0 | – | £0 | -£0 |
| % Margin | -3.5% | – | 3.2% | -6.6% |
| Other Income/Exp. Net | -£0 | – | -£0 | -£0 |
| Pre-Tax Income | -£0 | – | £0 | -£0 |
| Tax Expense | £0 | – | £0 | £0 |
| Net Income | -£0 | – | -£0 | -£0 |
| % Margin | -6.8% | – | -1.7% | -14.2% |
| EPS | -0.014 | – | -0.003 | -0.009 |
| % Growth | – | – | 65.9% | – |
| EPS Diluted | -0.014 | – | -0.003 | -0.009 |
| Weighted Avg Shares Out | 0 | – | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | – | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | – | £0 | £0 |
| Interest Expense | £0 | – | £0 | £0 |
| Depreciation & Amortization | £0 | – | £0 | £0 |
| EBITDA | £0 | – | £0 | £0 |
| % Margin | 0% | – | 6.4% | 5.2% |